Bios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and Surveillance

Bios Life, an innovative AI-driven cancer surveillance company, has officially launched from stealth mode with a substantial $25 million in seed funding. This funding round was spearheaded by Redmile, Vsquared Ventures, and Kindred Capital, with additional support from a collective of prominent healthcare and technology investors across the US and Europe.

The company is focused on creating a personalized surveillance strategy aimed at assisting high-risk individuals and cancer survivors, two demographics that often receive fragmented and reactive care. In the US alone, over 40 million people are either at increased risk for cancer or are cancer survivors. With more than 40% of individuals projected to be diagnosed with cancer during their lifetime, and over 30% of those cases identified at stages 3 or 4, Bios Life is addressing a critical need with its predictive care platform. This platform integrates advanced multi-modality foundation models with direct patient care, ensuring comprehensive support for these underserved populations. Additionally, the company has announced a strategic partnership with Tempus, a leader in AI-driven precision medicine, to enhance the training and validation of its predictive models.

Ryan Richardson, Co-founder and CEO of Bios Life, stated, "Tens of millions of high-risk individuals and cancer survivors lack access to cutting-edge care which is tailored to their particular needs and their unique biology. Bios Life is building a novel technology portfolio and specialized care delivery model to uniquely serve these individuals at a level that has not been possible until now – one that is deeply personalized and delivered at scale. The support of world-class partners and investors at launch gives us the foundation to become a category-defining company in this emerging space."

Bios Life aims to transform cancer care for survivors and high-risk patients by providing continuous, personalized, technology-enabled surveillance directly to them and in collaboration with leading cancer centers. The company plans to launch its platform in the US in the latter half of 2026, and consumers can currently join the waitlist at www.bioslife.ai.

Kevin Oeffinger, MD, Director of the Duke Cancer Institute Center for Onco-Primary Care, remarked, "Cancer screening and surveillance have been at a relative standstill for the past 20-30 years. The vast majority of individuals at elevated risk of cancer are not screened according to standard-of-care guidelines, and one out of every five newly diagnosed cancers in the US is found in cancer survivors. The AI-enhanced virtual model developed by Bios Life has the potential to greatly enhance the delivery of care to these high-risk populations; this is a game changer. Utilizing AI tools with a genetic and lifestyle backbone will move us from stagnation to the long-promised potential of personalized and precise cancer screening."

Bios Life's advanced AI technology platforms enable the delivery of tailored cancer surveillance and holistic supportive care for each individual's unique circumstances. This results in the creation of a digital twin for every patient, which continuously updates their biological model, shifting from isolated screening episodes to integrated lifetime surveillance. The core of Bios Life’s platform comprises proprietary technologies, including its Personalized Cancer Risk and Cancer Surveillance Platforms. The company has also secured commercial rights to the Nucleotide Transformer genomics foundation model from BioNTech-InstaDeep, recognized as one of the most cited AI genomics models globally, capable of analyzing genomic signals at a single-nucleotide level.

The alliance with Tempus allows Bios Life to utilize Tempus’ de-identified multi-modal oncology datasets to develop and deploy advanced predictive models for a variety of common cancers, transitioning from reactive scans to proactive, predictive modeling. Furthermore, in collaboration with Ambry Genetics, now part of Tempus, Bios Life plans to incorporate genetic screening into its preventive platform along with physician-ordered genetic testing within its survivorship program.

Ryan Fukushima, CEO of Data and Apps at Tempus, expressed, “At Tempus, we believe the future of cancer care isn’t just better treatments, it needs better prediction. Our collaboration with Bios Life is an opportunity to rethink how we identify, monitor and support individuals at elevated risk for cancer over the course of their lives. By bringing together Tempus’ multi-modal data platform, Ambry’s expertise in hereditary genetics, and Bios Life’s virtual-first care model, we can move beyond episodic screening toward a more continuous understanding of risk. The goal is simple but ambitious: support high-risk individuals and cancer survivors with a personalized surveillance strategy that evolves with them over time.”

Bios Life's leadership team is composed of seasoned professionals with extensive experience in oncology and health technology. Ryan Richardson, the Co-founder & CEO, previously served as the Chief Strategy Officer of BioNTech. Joining him are Co-founder and Chief Operating & Business Officer Zach Taylor, and Co-founder and Chief Medical Officer Logan Frank, MD, a board-certified radiologist. The team also includes technology experts such as Geoff Hyde, Head of Product and Engineering, and Thomas Pierrot, PhD, Head of Artificial Intelligence, both of whom bring significant expertise from their previous roles.

Individuals interested in early access to the platform can join the waitlist at www.bioslife.ai.